Clinical trial · Observational
Brain Oligometastasis in NSCLC
Management of Patients With Brain-onset Oligometastatic Non-small-cell Lung Cancer (NSCLC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Oligometastatic | Brain Neoplasm | PROBABILISTIC | 0.70 |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standard treatments / multiple strategies | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Local treatments
- description
- Local multimodal treatments (thoracic surgery/radiotherapy + brain surgery/radiotherapy)
- interventionNames
- Other: Standard treatments / multiple strategies
- label
- Systemic treatment
- description
- Chemoimmunotherapy combination
- interventionNames
- Other: Standard treatments / multiple strategies
Primary outcomes (1)
- measure
- Progression free survival (PFS)
- timeFrame
- Once, at progression or death from any cause
- description
- Time from random assignment in a clinical trial to disease progression or death from any cause
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Consecutive patients managed at Bordeaux University Hospital * Non-small-cell lung cancer * Oligometastatic brain cancer (fewer than 5 lesions at diagnosis) * Patient over 18 years old Exclusion Criteria: * Oncogenic addiction EGFR, ALK, ROS1 * Patient with concomitant cancer * Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage
References
Publications (0)
Data not yet available